HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

OSTX

OS Therapies Inc

Last Close
Mar 17 • 09:42AM ET
1.58
Dollar change
-0.03
Percentage change
-1.85 		%
Healthcare • Biotechnology • USA • AMEX
Peers: MRK PFE JNJ AMGN BMY GILD LLY REGN BIIB VRTX
Scroll to Statements
Index- P/E- EPS (ttm)- Insider Own35.18% Shs Outstand21.18M Perf Week-2.46%
Market Cap34.40M Forward P/E118.54 EPS next Y0.01 Insider Trans-1.50% Shs Float14.11M Perf Month-20.59%
Income- PEG- EPS next Q- Inst Own0.67% Short Float4.58% Perf Quarter-56.94%
Sales- P/S- EPS this Y168.60% Inst Trans-8.96% Short Ratio0.54 Perf Half Y-54.85%
Book/sh-0.03 P/B- EPS next Y-97.18% ROA- Short Interest0.65M Perf Year-
Cash/sh0.09 P/C18.50 EPS next 5Y- ROE- 52W Range1.41 - 7.00 Perf YTD-63.08%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-77.43% Beta-
Dividend TTM- Quick Ratio0.76 Sales past 5Y- Gross Margin- 52W Low12.07% ATR (14)0.24
Dividend Ex-Date- Current Ratio0.76 EPS Y/Y TTM- Oper. Margin- RSI (14)38.35 Volatility8.20% 12.47%
Employees- Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price14.67
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q-49.01% Payout- Rel Volume0.10 Prev Close1.61
Sales Surprise- EPS Surprise0.00% Sales Q/Q- EarningsFeb 26 Avg Volume1.20M Price1.58
SMA20-5.18% SMA50-36.57% SMA200-46.69% Trades Volume9,914 Change-1.85%
Mar-13-25 07:40AM
OS Therapies Awarded OST-HER2 Clinical Trial Data Presentation at MIB Agents FACTOR Osteosarcoma Conference
(Business Wire)
Mar-11-25 07:40AM
OS Therapies Schedules United Kingdoms Medicines and Healthcare products Regulatory Agency's (MHRA) Scientific Advice Meeting in the Third Quarter of 2025 for Review of its OST-HER2 Immunotherapy Candidate for Osteosarcoma
(Business Wire)
Feb-28-25 09:00AM
Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
(ACCESS Newswire)
Feb-26-25 04:01PM
Join OS Therapies Exclusive Live Investor Webinar and Q&A Session on February 27
(Business Wire)
Feb-24-25 07:25AM
OS Therapies Forms Subsidiary OS Drug Conjugates and Initiates Review of Strategic Options for its tunable ADC & Drug Conjugates Platforms
(Business Wire)
05:00AM Loading…
Feb-20-25 05:00AM
OS Therapies Receives Patent Notice of Allowance from U.S. Patent & Trademark Office Covering Commercial Manufacturing of OST-HER2
(Business Wire)
Feb-14-25 01:51PM
Small-Cap OS Therapies Inks Commercial Manufacture Agreements For Lead Cancer Drug For Rare Type Of Bone Cancer
(Benzinga) +12.06%
07:36AM
OS Therapies Initiates Commercial-ready Manufacturing of OST-HER2 to Support Anticipated Biologics Licensing Authorization (BLA) Filing
(Business Wire)
Feb-04-25 07:33AM
OS Therapies Provides Corporate Update
(Business Wire) +10.29%
Feb-03-25 08:30AM
RedChip Launches RedChat: Revolutionary AI Chatbot for Small-Cap Stock Analysis
(ACCESS Newswire)
Jan-30-25 09:35AM
OS Therapies to acquire listeria programs from Ayala Pharmaceuticals
(TipRanks) -25.00%
Jan-29-25 10:05AM
OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate Cancer Programs to Pipeline
(Business Wire)
Jan-17-25 08:35AM
OS Therapies price target raised to $15 from $8 at Maxim
(TipRanks) -28.40%
Jan-15-25 09:17AM
OS Therapies Announces Phase 2b Clinical Trial of OST-HER2 Achieves Primary Endpoint with Statistical Significance in the Prevention of Recurrent, Fully Resected, Lung Metastatic Osteosarcoma
(Business Wire)
Jan-02-25 11:16AM
OS Therapies to Attend the 43rd Annual J.P. Morgan Healthcare Conference
(Business Wire)
03:38PM Loading…
Dec-31-24 03:38PM
OS Therapies Announces Closing of $6 Million Private Placement
(Business Wire) -8.94%
Dec-26-24 12:04PM
OS Therapies Partners With B2i Digital to Engage With Biotech Investors Online
(NewMediaWire) +33.29%
Dec-25-24 09:40AM
OS Therapies to sell 1.5M units at $4.00 in private placement
(TipRanks)
Dec-24-24 09:32AM
OS Therapies Announces Pricing of $6 Million Private Placement
(Business Wire)
Nov-15-24 09:47AM
OS Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update
(Business Wire)
Nov-04-24 07:00AM
OS Therapies to Present at The Spartan Capital Investor Conference
(Business Wire)
Oct-30-24 08:51AM
Join OS Therapies Exclusive Live Investor Webinar and Q&A Session on October 30
(Business Wire)
Oct-28-24 04:44PM
OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors
(Business Wire) -8.69%
Oct-24-24 08:46AM
OS Therapies to Present at the LD Micro Main Event XVII
(Business Wire)
Oct-17-24 09:22AM
OS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
(Business Wire)
Oct-03-24 08:00AM
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Completes Last Patient Visit
(Business Wire)
Sep-13-24 08:09AM
OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates
(Business Wire)
Sep-12-24 07:59AM
Transforming Cancer Therapy Stocks to Watch In The Oncology Sector
(News Direct)
Sep-11-24 08:15AM
OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models
(ACCESSWIRE) -6.40%
Sep-05-24 08:22AM
OS Therapies to Present at H.C. Wainright 26th Annual Global Investment Conference
(Business Wire)
07:53AM Loading…
Aug-29-24 07:53AM
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose
(Business Wire)
Aug-22-24 08:00AM
OS Therapies Appoints Borys Shor, PhD to ADC Advisory Board
(Business Wire)
06:00AM
OS Therapies Clarifies CUSIP of Common Stock
(Business Wire)
Aug-21-24 05:00AM
The Future of Medicine: Key Biotech Stocks to Watch
(News Direct)
Aug-19-24 08:30AM
OS Therapies Accepted Into Johnson & Johnson Innovation - JLABS
(Business Wire) +14.66%
Aug-15-24 08:30AM
OS Therapies Reports Second Quarter 2024 Financial Results
(ACCESSWIRE) +12.03%
Aug-09-24 09:00AM
OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
(ACCESSWIRE) +33.78%
Aug-06-24 08:35AM
OS Therapies Announces Osteosarcoma Scientific and Medical Advisory Board
(ACCESSWIRE) +17.37%
Aug-02-24 08:55AM
OS Therapies Forms Osteosarcoma Patient Advocacy Advisory Board
(Business Wire) +59.36%
Jul-31-24 06:21PM
OS Therapies Announces Pricing of its Initial Public Offering on NYSE American - Company to Trade under Symbol "OSTX"
(Business Wire)
Jul-24-24 10:48AM
OS Therapies Announces Positive Safety Data from Phase 1 Clinical Trial of OST-HER2 in HER2-Expressing Breast Cancer and in Preclinical Efficacy in Models of Breast Cancer
(Business Wire)
Jun-03-24 12:44PM
OS Therapies Announces Positive Clinical Update from Ongoing Phase 2b Clinical Trial in Resected, Recurrent Osteosarcoma
(Business Wire)
OS Therapies, Inc. operates as a clinical stage biopharmaceutical company. It engages in identification, development, and commercialization of treatments for Osteosarcoma and other related diseases. The company was founded by Paul A. Romness on April 12, 2018 and is headquartered in Rockville, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Auerbach Shalom10% OwnerFeb 14 '25Sale2.84100,000284,3002,431,211Feb 18 09:00 PM
Auerbach Shalom10% OwnerJan 15 '25Sale6.7416,720112,6092,531,211Jan 17 07:00 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • help • privacy • do not sell my data
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.